BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Preventing neuronal necroptosis by disrupting the interaction between ASIC1A, an acid-sensing ion channel, RIPK1 and NSF could treat ischemic stroke. During acidosis, the interaction between ASIC1A’s C- and N-termini is...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

GSK has formally started the process of splitting its innovative R&D and consumer health businesses into two companies, while continuing to cull down its clinical pipeline. In its 4Q19 earnings Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
BC Innovations | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output. DNA-encoded library...
BC Extra | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

Emgality meets in Phase III in pretreated migraine patients  Eli Lilly and Co. (NYSE:LLY) reported that anti-CGRP mAb Emgality galcanezumab-gnlm met the primary endpoint in the Phase III CONQUER trial, reducing migraine headache days by...
BC Innovations | Jul 10, 2019
Distillery Therapeutics

Activating RIPK3 could help treat melanoma and lung cancer

DISEASE CATEGORY: Cancer INDICATION: Melanoma; lung cancer Activating RIPK3 could help treat melanoma and lung cancer. Among 228 skin cutaneous melanoma patients, high RIPK3 transcript levels were associated with longer survival. Intratumoral injection of matched...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Innovations | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BC Innovations | Mar 19, 2019
Distillery Therapeutics

New brain-penetrating RIPK2 inhibitor prodrug for GBM

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies identified a brain-penetrating naphthoquinone-based prodrug of a RIPK2 inhibitor that could help treat glioblastoma multiforme (GBM). Screening a library of drug-like small molecules in...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
Items per page:
1 - 10 of 45